CXCR4靶向放射性配体治疗在晚期弥漫性大B细胞淋巴瘤中的可行性
6例重度经治的复发弥漫性大B细胞淋巴瘤患者接受CXCR4靶向放射性配体治疗联合预处理化疗及异基因干细胞移植,其中2例加用靶向CD20或CD66的放射免疫治疗;治疗耐受良好,无急性不良事件,中位无进展生存期62天,中位总生存期76天,作者认为该方案作为移植前预处理方案可行。
要点
- 6例重度经治复发弥漫性大B细胞淋巴瘤患者接受CXCR4靶向放射性配体治疗联合预处理化疗及异基因干细胞移植。
- 治疗耐受良好,无急性不良事件或生命体征变化,中位植入时间11天(范围9-13天)。
- 4例可随访患者中2例部分缓解(均加用放射免疫治疗)、2例混合缓解,中位无进展生存期62天、中位总生存期76天。
核心结论
- CXCR4靶向放射性配体治疗(联合额外放射免疫治疗)作为弥漫性大B细胞淋巴瘤异基因干细胞移植前预处理方案是可行的。
研究设计与样本
- 6例重度经治的复发弥漫性大B细胞淋巴瘤患者(3男3女,年龄54±8岁)接受CXCR4靶向放射性配体治疗联合预处理化疗及异基因干细胞移植。
- 其中2例加用靶向CD20或CD66的放射免疫治疗以增强抗淋巴瘤活性。
- 终点为不良事件的发生率与严重程度、无进展生存期和总生存期。
主要发现
- 放射性配体治疗及额外放射免疫治疗耐受良好,无任何急性不良事件或生命体征变化。
- 中位植入时间11天(范围9-13天)。
- 4例可随访患者中,CXCR4靶向放射性配体治疗使2例部分缓解(均接受额外放射免疫治疗)、其余2例混合缓解。
- 1例在放射性配体治疗后29天死于中枢神经系统曲霉病,另1例在治疗后34天死于再生障碍期脓毒症。
- 缓解持续时间较短,中位无进展生存期62天(范围29-110天),中位总生存期76天(范围29-334天)。
临床怎么用
- 作者认为CXCR4靶向放射性配体治疗(联合额外放射免疫治疗)作为弥漫性大B细胞淋巴瘤异基因干细胞移植前预处理方案是可行的。
局限性
- 缓解持续时间较短,中位无进展生存期62天(范围29-110天),中位总生存期76天(范围29-334天)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have recently reported on our experience with C-X-C-motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54 ± 8 y) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation. In 2 patients, radioimmunotherapy targeting CD20 or CD66 was added to enhance antilymphoma activity. Endpoints were incidence and severity of adverse events, progression-free survival, and overall survival. Results: RLT and additional radioimmunotherapy were well tolerated, without any acute adverse events or changes in vital signs. Successful engraftment was recorded after a median of 11 d (range, 9-13 d). Of the 4 patients who were available for follow-up (one patient died of CNS aspergillosis 29 d after RLT and another of sepsis in aplasia 34 d after RLT), CXCR4-directed RLT resulted in a partial response in two (both treated with additional radioimmunotherapy) and a mixed response in the remaining two. The response duration was rather short-lived, with a median progression-free survival of 62 d (range, 29-110 d) and a median overall survival of 76 d (range, 29-334 d). Conclusion: CXCR4-directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma.
引用
- Lapa C, Hänscheid H, Kircher M, et al. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. J Nucl Med. 2018. PMID: 29777009. doi:10.2967/jnumed.118.210997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。